Metastatic Medullary Thyroid Cancer (MTC): Is There a Role for Peptide Receptor Radionuclide Therapy (PRRT)?

被引：0
|
作者：
Hayes, A. R. [1 ]
Crawford, A. [2 ]
Al Riyami, K. [3 ]
Tang, C. [4 ]
Wild, D. [5 ]
Khoo, B. [1 ]
Caplin, M. [1 ]
Nicolas, G. [5 ]
Grossman, A. B. [1 ]
机构：
[1] Royal Free Hosp, Neuroendocrine Tumour Unit, ENETS Ctr Excellence, London, England
[2] UCL, Med Sch, London, England
[3] Univ Coll London Hosp, Dept Nucl Med, London, England
[4] Univ Coll London Hosp, Dept Radiol, London, England
[5] Univ Hosp Basel, Div Nucl Med, Basel, Switzerland
来源：
NEUROENDOCRINOLOGY | 2019年 / 108卷
关键词：
medullary thyroid cancer; mtc; sstr expression; prrt; 90y; 177lu;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
N03
引用
收藏
页码：273 / 273
页数：1
相关论文
共 50 条
  • [1] Is There a Role for Peptide Receptor Radionuclide Therapy in Medullary Thyroid Cancer?
    Vaisman, Fernanda
    Rosado de Castro, Paulo Henrique
    Proenca Lobo Lopes, Flavia Paiva
    Kendler, Daniel Barretto
    Pessoa, Cencita H. N.
    Bulzico, Daniel Alves
    Leal, Douglas de Carvalho
    Vilhena, Bruno
    Vaisman, Mario
    Carneiro, Michel
    Corbo, Rossana
    [J]. CLINICAL NUCLEAR MEDICINE, 2015, 40 (02) : 123 - 127
  • [2] Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues
    Salavati, Ali
    Puranik, Arneya
    Kulkarni, Harshad R.
    Budiawan, Hendra
    Baum, Richard P.
    [J]. SEMINARS IN NUCLEAR MEDICINE, 2016, 46 (03) : 215 - 224
  • [3] PEPTIDE RECEPTOR RADIONUCLIDE THERAPY FOR METASTATIC MEDULLARY THYROID CARCINOMA: A WESTERN AUSTRALIAN EXPERIENCE
    Pugazhenthi, Kamali
    [J]. INTERNAL MEDICINE JOURNAL, 2023, 53 : 43 - 43
  • [4] The role of radionuclide therapy in medullary thyroid cancer
    Castellani, MR
    Alessi, A
    Savelli, G
    Bombardieri, E
    [J]. TUMORI, 2003, 89 (05) : 560 - 562
  • [5] THE NURSES ROLE IN PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) WITH LUTATHERA
    Longing, Anne
    Boswell, Abigail
    Kennedy, Matthew
    [J]. ONCOLOGY NURSING FORUM, 2019, 46 (02)
  • [6] AN ALTERNATIVE THERAPY OPTION IN METASTATIC THYROID CANCER: PEPTIDE RECEPTOR RADIONUCLIDE THERAPY
    Cinkir, Havva Yesil
    Elboga, Umut
    [J]. JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, 2020, 83 (04): : 339 - 344
  • [7] Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy
    Hayes, Aimee R.
    Crawford, Alexander
    Al Riyami, Khulood
    Tang, Christine
    Bomanji, Jamshed
    Baldeweg, Stephanie E.
    Wild, Damian
    Morganstein, Daniel
    Harry, Alice
    Grozinsky-Glasberg, Simona
    Oleinikov, Kira
    Khoo, Bernard
    Caplin, Martyn E.
    Nicolas, Guillaume P.
    Grossman, Ashley B.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (12): : E4903 - E4916
  • [8] Peptide Receptor Radionuclide Therapy (PRRT) in a Patient Affected by Metastatic Breast Cancer with Neuroendocrine Differentiation
    Savelli, Giordano
    Zaniboni, Alberto
    Bertagna, Francesco
    Bosio, Giovanni
    Nisa, Lutfun
    Rodella, Carlo
    Biasiotto, Giorgio
    Bettinsoli, Giovanni
    Migliorati, Elena
    Peli, Alessia
    Falchi, Roberta
    Giuffrida, Francesca
    Giubbini, Raffaele
    [J]. BREAST CARE, 2012, 7 (05) : 408 - 410
  • [9] Peptide Receptor Radionuclide Therapy in Thyroid Cancer
    Gubbi, Sriram
    Koch, Christian A.
    Klubo-Gwiezdzinska, Joanna
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [10] Personalized cancer therapy for patients with metastatic medullary thyroid cancer (MTC).
    Misiukiewicz, Krzysztof
    Winder, Lewis
    Posner, Marshall R.
    Genden, Eric Michael
    Zhang, David Y.
    Cagan, Ross L.
    Donovan, Michael J.
    Schadt, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345